PIONEER REAL Spain : A multicentre, prospective, real‐world study of oral semaglutide use in adults with type 2 diabetes
Authors' conclusion
Oral semaglutide treatment improved glycaemic control and reduced body weight in Spanish clinical practice. Early intervention and SGLT2i co-treatment were associated with more favourable outcomes.
Study context
- Population
- Adults with T2D naïve to injectable glucose-lowering medication, routine clinical practice in Spain (part of 13-country PIONEER REAL programme)430 completed
- Outcome
- Change in HbA1c from baseline to end of study (EOS)
- Follow-up
- 34-44 weeks
Methodological detailsmulticentre, non-interventional, post hoc stratification
- Multicentre
- Non-interventional
- Post hoc stratification
Main finding
As reported in the abstract
Change in HbA1c · EOS
Estimated change in HbA1c
−1.4%-points
95% CI −1.5, −1.3p < 0.0001
Observational data: associations, not effects.
Secondary outcomes
Change in body weight · end of study (EOS)
- Estimated change in body weight
- −6.8% (95% CI −7.4, −6.1; p < 0.0001)
Change in HbA1c by SGLT2i co-use · EOS
- With SGLT2i
- −1.8%-points (95% CI −2.1, −1.6; p < 0.0001)
- Without SGLT2i
- −1.2%-points (95% CI −1.3, −1.1; p < 0.0001)
- Post hoc
Change in HbA1c by T2D duration · EOS
- T2D duration ≤5 years
- −1.4%-points (95% CI −1.6, −1.3; p < 0.0001)
- T2D duration >5 years
- −1.2%-points (95% CI −1.3, −1.0; p < 0.0001)
- Post hoc
HbA1c <7% · EOS
- Participants achieving HbA1c <7%
- 77.4%
≥1%-point HbA1c reduction and ≥5% body weight reduction · EOS
- Participants achieving both
- 33.3%
Treatment satisfaction
- Treatment satisfaction increased
Safety
- No new safety concerns were identified
Original publication
PIONEER REAL Spain : A multicentre, prospective, real‐world study of oral semaglutide use in adults with type 2 diabetes. Diabetes Obes Metab. Published 24 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →